Beneficial effect of Lactobacillus gasseri BNR17 on irritable bowel syndrome. - GreenMedInfo Summary
Effect ofBNR17 on irritable bowel syndrome: a randomized, double-blind, placebo-controlled, dose-finding trial.
Food Sci Biotechnol. 2018 Jun ;27(3):853-857. Epub 2017 Dec 12. PMID: 30263811
Ji Yeon Kim
BNR17 is a strain isolated from human breast milk. The objective of this randomized, double-blind, placebo-controlled, and preliminary dose-finding trial was to find the effective dose and evaluate the effect ofBNR17 on irritable bowel syndrome (IBS) symptoms. A total of 55 volunteers aged over 20 years with body mass index over 23 kg/mwere randomized to intake a placebo, low-dose (BNR-L, 2 × 10 CFU/day), intermediate-dose (BNR-M, 2 × 10 CFU/day), or high-dose BNR (BNR-H, 2 × 5 × 10 CFU/day) for four weeks. Questionnaire for IBS symptoms scores andBNR17 in feces were assessed at the beginning and end of the trial. Among IBS symptoms scores, abdominal pain score was significantly reduced in BNR-H group.BNR17 was detected in all intake groups except placebo. In the preliminary study,BNR17 was confirmed to have probiotic properties.